HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/5/G1263    most recent 00409.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Katchar, K. Articles by Keates, A. C. Search for Related Content PubMed PubMed Citation Articles by Katchar, K. Articles by Keates, A. C.

INFLAMMATION/IMMUNITY/MEDIATORS

MIP-3 neutralizing monoclonal antibody protects against TNBS-induced colonic injury and inflammation in mice

¹Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, and ²Mallory Institute of Pathology, Boston University School of Medicine, Boston, Massachusetts

Submitted 1 September 2006 ; accepted in final form 29 January 2007

A characteristic feature of human inflammatory bowel disease, particularly Crohn's disease, is the presence of activated CD4⁺ T cells. Recently, we have shown that colonic epithelial cell production of macrophage inflammatory protein (MIP)-3, a CD4 T cell-directed chemokine, is elevated in inflammatory bowel disease. However, the functional relevance of MIP-3 production during intestinal inflammation is poorly understood. The aim of this study was to determine whether MIP-3 production is increased during murine 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis and to examine the effect of anti-MIP-3 neutralizing monoclonal antibody administration in this model. We found that the administration of TNBS significantly increased colonic MIP-3 protein levels in Balb/c mice. Consistent with this, a marked increase in the number of CCR6-bearing lamina propria CD4⁺ and CD8⁺ T cells was also observed in TNBS-treated animals. Treatment of mice with an anti-MIP-3 neutralizing monoclonal antibody significantly reduced TNBS-mediated increases in colonic weight-to-length ratio, mucosal ulceration, histological damage, and myeloperoxidase activity. TNBS-mediated increases in the number of CCR6-bearing lamina propria T cells were also substantially reduced by anti-MIP-3 neutralizing monoclonal antibody treatment. Taken together, our findings indicate that blockade of MIP-3 bioactivity can significantly reduce TNBS-mediated colonic injury and T cell recruitment, suggesting a role for this chemokine in the pathophysiology of intestinal inflammation.

chemokine; inflammatory bowel disease; colitis; CD4; T lymphocyte; 2,4,6-trinitrobenzene sulfonic acid